Table 5.
Compounds | IC50 (μM) a |
---|---|
7 | 0.44 ± 0.01*** |
8 | 0.47 ± 0.03*** |
21 | 0.53 ± 0.01*** |
Sorafenib | 5.50 ± 1.50 |
Human endothelial progenitor cells were treated with the indicated compounds for 48 h. Anti-angiogenic activity was evaluated in a cell growth assay. Data are displayed as the mean ± SEM. Sorafenib, a well-known anti-angiogenic agent, was used as a positive control.